TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years.~* A clinical diagnosis of MINOCA within the last 30 days.~* Left ventricular ejection fraction ≥40% measured with echocardiography, MRI or left ventriculography after admission and prior to randomization.~* Written informed consent obtained~Exclusion Criteria:~* Any condition that may influence the patient's ability to comply with study protocol.~* Previous revascularization (CABG or PCI)~* Clinical signs of heart failure~* MRI-proven myocarditis or a strong clinical suspicion of myocarditis or takotsubo as cause of the index event~* Contraindications for Beta blocker treatment~* Contraindications for ACEI and ARB treatment~* Prior use of ACEI, ARB, or Beta blockers, which must continue according to treating physician.~* New indication for Beta blocker or ACEI/ARB treatment other than as secondary prevention according to treating physician~* Ongoing pregnancy or woman of childbearing potential not using adequate contraceptives~* Participation in a trial evaluating a drug known to interact with Beta blockers or ACEI/ARB

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Beta blocker and no ACEI/ARB (Type: NO_INTERVENTION): No Beta blocker and no ACEI/ARB
- Beta blocker and ACEI/ARB (Type: EXPERIMENTAL): Beta blocker and either ACE inhibitor or Angiotensin receptor blocker
- Beta blocker alone (Type: EXPERIMENTAL): Beta blocker alone
- ACEI/ARB alone (Type: EXPERIMENTAL): Either ACE inhibitor or Angiotensin receptor blocker alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mechano-physiological Approach to Anorectal Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Controls~Inclusion Criteria:~* Women~* No defecatory problems~* On no medication which affect bowel habits~Exclusion Criteria:~* Pregnancy~Patients~Inclusion Criteria:~* Difficulty in defecation~* Women~Exclusion criteria:~* Pregnancy~* Medication which can affect bowel movement

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified intra- or extrahepatic inoperable hepatocellular carcinoma or hyperdense liver lesion at computed tomography and concurrent elevated alpha-feto-protein \> 400 ng/ml~* PS 0-2~* Age 18-75~* Life expectancy \> 12 weeks~* Normal bone marrow function (neutrophiles \> 1,5 x 109/l and platelets \> 100 x 109/l)~* Bilirubin \< 2 x UNL~* Transaminases \< 3 x UNL~* Normal renal function, Cr-EDTA clearance \> 50 ml/min~* No chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion~* No uncontrolled, severe concurrent medical disease~* Fertile women must have a negative pregnancy test~* Fertile women must use adequate contraceptives during and 3 months after trial exposure~* Signed informed consent~Exclusion Criteria:~* Chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion~* Experimental therapy \< 8 weeks prior to inclusion~* Known DPD-deficiency~* Known neuropathy~* Uncontrolled, severe concurrent medical disease~* Prior malignancy during the last 5 years, except for non-melanoma skin cancer and carcinoma in situ cervix uteri.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of XL019 in Adults With Myelofibrosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject has primary myelofibrosis (PMF), post-polycythemia vera MF, or post-essential thrombocythemia MF and requires therapy, including subjects who have received prior MF-directed therapy and relapsed or subjects with refractory disease; or if newly diagnosed, then with intermediate or high risk according to the Lille scoring system.~* The subject is unwilling to undergo or is not a candidate for peripheral stem cell/bone marrow transplant.~* The subject is ≥18 years old.~* The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.~* The subject has adequate organ function.~* The subject has the capability of understanding the informed consent document and has signed the informed consent document.~* Sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study.~* Female subjects of childbearing potential must have a negative pregnancy test at screening.~* The subject has had no diagnosis of malignancy or evidence of other malignancy for 2 years prior to screening for this study (except non-melanoma skin cancer or in situ carcinoma of the cervix).~Exclusion Criteria:~* The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within 3 months, or cardiac arrhythmias.~* The subject is pregnant or breastfeeding.~* The subject is known to be positive for the human immunodeficiency virus (HIV).~* The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Changes in fMRI and Neurocognitive Function in Women With Pre-eclampsia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:Severe Pre-Eclampsia defined by~* Symptoms of central nervous system dysfunction (New onset cerebral or visual disturbance, such as: Photopsia, scotomata, cortical blindness, retinal vasospasm)~* Severe headache (ie, incapacitating, the worst headache I've ever had) or headache that persists and progresses despite analgesic therapy~* Altered mental status~* Hepatic abnormality (Severe persistent right upper quadrant or epigastric pain unresponsive to medication and not accounted for by an alternative diagnosis or serum transaminase concentration ≥ twice normal, or both)~* Severe blood pressure elevation (Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg on two occasions at least four hours apart while the patient is on bedrest (unless the patient is on antihypertensive therapy))~* Thrombocytopenia (\<100,000 platelets/microL)~* Renal abnormality (Progressive renal insufficiency (serum creatinine \>1.1 mg/dL or doubling of serum creatinine concentration in the absence of other renal disease))~* Pulmonary edema~  15 English-speaking pregnant controls with uncomplicated pregnancy matched by age and gestational age will be enrolled from the antenatal clinic or the labor ward.~Exclusion Criteria:~* History of symptomatic cerebrovascular disease with substantial residual deficit~* History of alcoholism~* History of psychiatric illness~* History of claustrophobia~* Renal failure (creatinine \> 2.0 mg/dl)~* Patients with less than a 7th grade education or unable to read and thus unable complete the neuropsychological testing~* Patients with bodily implants unsafe for MRI use

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Pre-Eclampsia (Type: None): 15 English-speaking women with severe pre-eclampsia
- Control (Type: None): 15 English-speaking pregnant controls with uncomplicated pregnancy matched by age and gestational age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aneurysmal subarachnoid hemorrhage~* World Federation of Neurological Surgeons (WFNS) grade 4-5 (see table below)~* Surgical intervention with clip or coil~* Placement of cerebrospinal fluid drain (lumbar or ventricular)~* Mechanically ventilated at start of infusion~Exclusion Criteria:~* Hemodynamic instability (SBP \< 100, HR \<60, or on continuous infusion of catecholamines) at screening~* Heart failure class III or IV (New York Heart Association)~* Renal failure (RIFLE classification - see table below)~* Liver failure (serum protein \< 3 g/dL and total bilirubin \> 5 mg/dL)~* Known or suspected brain death~* Pregnancy~* Unable to receive dexmedetomidine within 48 hours of injury and 4 hours of surgery~* Allergy to dexmedetomidine~* Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propofol (Type: ACTIVE_COMPARATOR): None
- Dexmedetomidine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Currently reside in the USA~* Ability to comply with follow up visits at 2-4 months and at 6 months~* Come to the last follow-up at 6 months in the clinic~* At least 5% Body Surface Area (BSA) affected with AD~Exclusion Criteria:~* Unclear diagnosis of atopic dermatitis~* Inability to comply with additive baths~* Inability to comply with follow-up visits~* Lack of residence in the United States

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Water (Type: ACTIVE_COMPARATOR): Subjects will bathe at least twice a week in a water bath for 6 months and keep a record of their bathing regimen
- Bleach (Type: ACTIVE_COMPARATOR): Subjects will bathe at least twice a week in a water + dilute bleach bath for 6 months and keep a record of their bathing regimen
- Acetic acid (Type: ACTIVE_COMPARATOR): Subjects will bathe at least twice a week in a water bath + vinegar for 6 months and keep a record of their bathing regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years~* Newly diagnosed atrial fibrillation or flutter~* Patients with atrial fibrillation or flutter that occurred within 7 days after non-cardiac non-thoracic surgery~* Atrial fibrillation or flutter with rapid ventricular response(HR ≥110/min)~* Patients without hemodynamic instability (MBP≥65mmHg with norepinephrine continuous infusion less than 5mcg/min or without vasopressor support)~Exclusion Criteria:~* Atrial fibrillation or flutter prolonged more than 48 hours without anticoagulation~* Patients who have decreased cardiac function or heart failure (EF \<40%)~* Patients who have cardiac conduction disorder, QT prolongation(QTc ≥500ms)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rate control strategy group (Type: EXPERIMENTAL): Patients are given diltiazem or esmolol to control heart rate less than 110/min.
- Rhythm control strategy group (Type: EXPERIMENTAL): Patients are given amiodarone for conversion of cardiac rhythm to sinus rhythm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic adrenal insufficiency~* Written informed consent/assent in compliance with applicable country-specific and local regulations~Exclusion Criteria:~* Participation in an interventional clinical trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plenadren (Type: None): Modified release hydrocortisone
- Other Glucocorticoid Replacement Therapy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics and the Prevention of Traveler's Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects aged 18 or over. Upper age limit set by subject's ability to participate in the study;~2. Subject must give written informed consent;~3. Plan to travel to a geographic area with high risk of TD with a travel duration between 12 and 14 days;~4. Subjects must be willing to refrain from using anti-diarrheal medications or antibiotics during the study period, unless they become clinically indicated in which case a rescue regimen can be administered;~5. Subjects willing to refrain from eating yoghurt and taking other probiotics during the study;~6. Female subjects of child-bearing potential must agree to use adequate birth control during the study period. This will be defined as hormonal contraception or a double barrier-method.~Exclusion Criteria:~1. Subjects who have been previously treated with PROTECFLOR® or who have participated in previous Lallemand-sponsored studies;~2. Subjects who have been born in a developing country.~3. Subjects with a history of substance or alcohol abuse or any other psychological condition that may, in the investigator's opinion, adversely affect their co-operation with the study;~4. Subjects who receive a cholera vaccine~5. Subjects with chronic diarrhea;~6. Subjects with chronic disease such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) or ulcerative colitis (UC) ;~7. Subjects with gastrointestinal (GI) surgery during the last 3 months;~8. Subjects who took systemic antibiotic 15 days or less prior to the study;~9. Subjects with immunodeficiency's or immune suppression;~10. Subjects being treated for cancer with radiotherapy and/or chemotherapy;~11. Subjects with organ transplants;~12. Subjects treated with immunosuppressant drugs;~13. Subjects receiving another probiotic preparations or having received probiotic preparations within the last 15 days;~14. Subjects with tube feeding, ileostomy and colostomy;~15. Subjects diagnosed Clostridium difficile colitis within the last 3 months;~16. Women who are pregnant, or who will not consent to using adequate birth control during the study period;~17. Women who are breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Protecflor (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Premature Ventricular Contractions (PVCs) and Blood Pressure Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Frequent symptomatic premature ventricular contractions (PVCs) (\>10% of total QRSs on a 24-hour Holter)~* Willingness to participate in research~Exclusion Criteria:~* Age \> 65 years old~* Pacemaker implantation~* Implantable cardioverter defibrillator implantation requiring pacing~* Sick sinus syndrome~* Atrio-ventricular (AV) block~* Left ventricular dysfunction defined as left ventricular ejection fraction \< 50%~* History of myocardial infarction or coronary artery disease~* Severe left ventricular hypertrophy (wall thickness \> 1.5 cm by echocardiography performed within 3 months from enrollment)~* Severe liver dysfunction~* Creatinine clearance of 35 mL/min/1.73 square meters or less~* Pregnancy~* Known hypersensitivity to the drug~* QRS duration \> 120 ms~* Recent change in blood pressure medication within 30 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PVC Suppression then Placebo (Type: PLACEBO_COMPARATOR): This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
- Placebo then PVC Suppression (Type: PLACEBO_COMPARATOR): This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Patients with early stage biopsy-proven lung cancer or patients with lung or liver metastases from any primary cancer (metastatic disease proven by biopsy, or clearly established clinically and by imaging studies who are being treated with stereotactic body radiotherapy (SBRT)or an ablation will be eligible.~* Patient has at least one lesion ≥ 1cm in size.~* Signed informed consent~Exclusion Criteria:~* Pregnant women are ineligible.~* Patients who are unable to follow breathing instructions either due to language difficulties or hearing impairment This will be determined either by one of the consenting individuals when they approach the patient to ask for informed consent or prior to acquisition of the clinical PET/CT.~* Patients who are too ill to hold their breath.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET/CT and BH PET/CT (Type: EXPERIMENTAL): In collaboration with the Department of Radiation Oncology and the Interventional Radiology Service, patients with lung or liver cancer or lung or liver metastases in whom FDG PET/CT is part of the clinical standard of care for disease evaluation and response assessment will be enrolled in this study. We will perform a clinical PET/CT and BH PET/CT (for two bed positions covering the entire chest) prior to, and again 1-2 weeks after SBRT or RFA. This early time point is chosen because a few weeks after the completion of treatment, acute radiation injury in the lung begins and will likely be detectable as abnormal uptake on follow-up PET imaging making it difficult to assess tumor recurrence.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues